• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种纳米结构脂质体系,用于提高钌(II)配合物的口服生物利用度,以治疗由……引起的感染。

A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by .

作者信息

da Silva Patricia B, de Freitas Eduardo Sinésio, Solcia Mariana Cristina, de Souza Paula Carolina, da Silva Monize Martins, Batista Alzir Azevedo, Eismann Carlos E, Rolisola Ana Marta C M, Menegário Amauri A, Cardoso Rosilene Fressatti, Chorilli Marlus, Pavan Fernando R

机构信息

School of Pharmaceutical Sciences, Universidade Estadual Paulista, Araraquara, Brazil.

Department of Chemistry, Universidade Federal de São Carlos, São Carlos, Brazil.

出版信息

Front Microbiol. 2018 Dec 6;9:2930. doi: 10.3389/fmicb.2018.02930. eCollection 2018.

DOI:10.3389/fmicb.2018.02930
PMID:30574128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6291527/
Abstract

Tuberculosis (TB) is an infectious, airborne disease caused by the bacterium that mainly affects the lungs. Fortunately, tuberculosis is a curable disease, and in recent years, death rates for this disease have decreased. However, the existence of antibiotic-resistant strains and the occurrence of co-infections with human immunodeficiency virus (HIV), have led to increased mortality in recent years. Another area of concern is that one-third of the world's population is currently infected with in its latent state, serving as a potential reservoir for active TB. In an effort to address the failure of current TB drugs, greater attention is being given to the importance of bioinorganic chemistry as an ally in new research into the development of anti-TB drugs. Ruthenium (Ru) is a chemical element that can mimic iron (Fe) in the body. In previous studies involving the following heteroleptic Ru complexes, [Ru(pic)(dppb)(bipy)]PF (SCAR1), [Ru(pic)(dppb)(Me-bipy)]PF (SCAR2), [Ru(pic)(dppb)(phen)]PF (SCAR4), -[Ru(pic)(dppe)]PF (SCAR5), and [Ru(pic)(dppe)(phen)]PF (SCAR7), we observed excellent anti-TB activity, moderate cell-toxicity, and a lack of oral bioavailability in an model of these complexes. Therefore, the objective of this study was to evaluate the toxicity and oral bioavailability of these complexes by loading them into a nanostructured lipid system. The nanostructured lipid system was generated using different ratios of surfactant (soybean phosphatidylcholine, Eumulgin, and sodium oleate), aqueous phase (phosphate buffer with a concentration of 1X and pH 7.4), and oil (cholesterol) to generate a system for the incorporation of Ru(II) compounds. The anti-TB activity of the compounds was determined using a microdilution assay with Resazurin (REMA) against strains of s HRv and clinical isolates resistant. Cytotoxicity assay using J774.A1 cells (ATCC TIB-67) and intra-macrophage activity were performed. The oral bioavailability assay was used to analyze blood collected from female BALB/C mice. Plasma collected from the same mice was analyzed via inductively coupled plasma mass spectrometry (ICP-MS) to quantify the number of Ru ions. The complexes loaded into the nanostructured lipid system maintained activity and toxicity was found to be reduced compared with the compounds that were not loaded. The complexes showed intra-macrophagic activity and were orally bioavailable.

摘要

结核病(TB)是一种由细菌引起的传染性空气传播疾病,主要影响肺部。幸运的是,结核病是一种可治愈的疾病,近年来,这种疾病的死亡率有所下降。然而,耐抗生素菌株的存在以及与人类免疫缺陷病毒(HIV)合并感染的发生,导致近年来死亡率上升。另一个令人担忧的领域是,目前世界三分之一的人口处于潜伏感染状态,成为活动性结核病的潜在储存库。为了解决当前结核病药物的疗效不佳问题,生物无机化学作为抗结核病药物开发新研究的盟友,其重要性正受到更多关注。钌(Ru)是一种能在体内模拟铁(Fe)的化学元素。在先前涉及以下杂配钌配合物的研究中,[Ru(pic)(dppb)(bipy)]PF(SCAR1)、[Ru(pic)(dppb)(Me - bipy)]PF(SCAR2)、[Ru(pic)(dppb)(phen)]PF(SCAR4)、-[Ru(pic)(dppe)]PF(SCAR5)和[Ru(pic)(dppe)(phen)]PF(SCAR7),我们在这些配合物的动物模型中观察到了出色的抗结核活性、适度的细胞毒性以及缺乏口服生物利用度。因此,本研究的目的是通过将这些配合物负载到纳米结构脂质系统中来评估它们的毒性和口服生物利用度。使用不同比例的表面活性剂(大豆磷脂酰胆碱、聚山梨酯和油酸钠)、水相(浓度为1X且pH值为7.4的磷酸盐缓冲液)和油(胆固醇)生成纳米结构脂质系统,以构建用于掺入Ru(II)化合物的体系。使用刃天青(REMA)微量稀释法针对敏感的H37Rv菌株和临床分离耐药菌株测定化合物的抗结核活性。使用J774.A1细胞(ATCC TIB - 67)进行细胞毒性测定和巨噬细胞内活性测定。口服生物利用度测定用于分析从雌性BALB/C小鼠采集的血液。通过电感耦合等离子体质谱(ICP - MS)分析从同一小鼠采集的血浆,以定量Ru离子的数量。负载到纳米结构脂质系统中的配合物保持了活性,并且发现与未负载的化合物相比毒性降低。这些配合物表现出巨噬细胞内活性并且具有口服生物利用度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/15d939feb591/fmicb-09-02930-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/8167bcd6ad77/fmicb-09-02930-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/83daff1e13b5/fmicb-09-02930-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/15d939feb591/fmicb-09-02930-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/8167bcd6ad77/fmicb-09-02930-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/83daff1e13b5/fmicb-09-02930-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc08/6291527/15d939feb591/fmicb-09-02930-g003.jpg

相似文献

1
A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by .一种纳米结构脂质体系,用于提高钌(II)配合物的口服生物利用度,以治疗由……引起的感染。
Front Microbiol. 2018 Dec 6;9:2930. doi: 10.3389/fmicb.2018.02930. eCollection 2018.
2
Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis.钌(II)膦/二亚胺/吡啶甲酸盐配合物:作为抗结核药物的无机化合物。
Eur J Med Chem. 2011 Oct;46(10):5099-107. doi: 10.1016/j.ejmech.2011.08.023. Epub 2011 Aug 23.
3
In Vitro Activity of Copper(II) Complexes, Loaded or Unloaded into a Nanostructured Lipid System, against Mycobacterium tuberculosis.负载或未负载到纳米结构脂质体系中的铜(II)配合物对结核分枝杆菌的体外活性
Int J Mol Sci. 2016 May 17;17(5):745. doi: 10.3390/ijms17050745.
4
Antiparasitic activities of novel ruthenium/lapachol complexes.新型钌/拉帕醇配合物的抗寄生虫活性
J Inorg Biochem. 2014 Jul;136:33-9. doi: 10.1016/j.jinorgbio.2014.03.009. Epub 2014 Mar 27.
5
Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds.纳米结构脂质体系作为一种改善钌(II)化合物体外细胞毒性的策略。
Molecules. 2014 May 9;19(5):5999-6008. doi: 10.3390/molecules19055999.
6
Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding.非致突变性 Ru(ii) 配合物:细胞毒性、拓扑异构酶 IB 抑制、DNA 和 HSA 结合。
Dalton Trans. 2019 Oct 7;48(39):14885-14897. doi: 10.1039/c9dt01905g.
7
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
8
Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.含氯喹和螯合配体的钌(II)钢琴凳配合物对乳腺和肺癌细胞的细胞毒性:与DNA和牛血清白蛋白的相互作用
J Inorg Biochem. 2015 Dec;153:150-161. doi: 10.1016/j.jinorgbio.2015.07.016. Epub 2015 Jul 23.
9
Synthesis, characterization, X-ray structure and in vitro antimycobacterial and antitumoral activities of Ru(II) phosphine/diimine complexes containing the "SpymMe2" ligand, SpymMe2=4,6-dimethyl-2-mercaptopyrimidine.含“SpymMe2”配体(SpymMe2 = 4,6 - 二甲基 - 2 - 巯基嘧啶)的钌(II)膦/二亚胺配合物的合成、表征、X射线结构以及体外抗分枝杆菌和抗肿瘤活性
J Inorg Biochem. 2008 Sep;102(9):1783-9. doi: 10.1016/j.jinorgbio.2008.05.009. Epub 2008 May 29.
10
Tuberculosis结核病

引用本文的文献

1
Breaking barriers: The potential of nanosystems in antituberculosis therapy.突破障碍:纳米系统在抗结核治疗中的潜力
Bioact Mater. 2024 May 17;39:106-134. doi: 10.1016/j.bioactmat.2024.05.013. eCollection 2024 Sep.
2
In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an -Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against .酰腙衍生物磷酸二酯酶-4抑制剂LASSBio-1386在体外、体内和计算机模拟中的有效性,针对…… (原文此处不完整)
Front Pharmacol. 2020 Dec 16;11:590544. doi: 10.3389/fphar.2020.590544. eCollection 2020.

本文引用的文献

1
Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.基于纳米技术的用于控制微生物生物膜的药物递送系统:综述
Int J Nanomedicine. 2018 Feb 27;13:1179-1213. doi: 10.2147/IJN.S146195. eCollection 2018.
2
Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion.通过基于 α-亚麻酸的微乳液提高非洛地平的生物利用度。
Drug Deliv Transl Res. 2018 Feb;8(1):204-225. doi: 10.1007/s13346-017-0453-9.
3
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
具有体内杀菌抗结核活性的含氮氧化物杂环的设计、合成与表征
J Med Chem. 2017 Oct 26;60(20):8647-8660. doi: 10.1021/acs.jmedchem.7b01332. Epub 2017 Oct 16.
4
Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis.细胞壁:结核分枝杆菌中多功能的药物靶点源泉。
Biomed Pharmacother. 2017 Nov;95:1520-1534. doi: 10.1016/j.biopha.2017.09.036. Epub 2017 Sep 21.
5
In Vitro Activity of Copper(II) Complexes, Loaded or Unloaded into a Nanostructured Lipid System, against Mycobacterium tuberculosis.负载或未负载到纳米结构脂质体系中的铜(II)配合物对结核分枝杆菌的体外活性
Int J Mol Sci. 2016 May 17;17(5):745. doi: 10.3390/ijms17050745.
6
Tuberculosis: An Inorganic Medicinal Chemistry Perspective.结核病:无机药物化学视角
Curr Med Chem. 2015;22(18):2199-224. doi: 10.2174/0929867322666150408112357.
7
Antitubercular activity of Ru (II) isoniazid complexes.钌(II)异烟肼配合物的抗结核活性
Eur J Pharm Sci. 2015 Apr 5;70:45-54. doi: 10.1016/j.ejps.2015.01.008. Epub 2015 Jan 28.
8
Recent advances in nanoparticle carriers for coordination complexes.用于配位化合物的纳米颗粒载体的最新进展。
Curr Top Med Chem. 2015;15(4):287-97. doi: 10.2174/1568026615666150108145614.
9
New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks.基于亲和与阴离子交换整体柱盘联合液相色谱法对人血清中钌基化疗药物进行形态分析的新方法
J Chromatogr A. 2014 Dec 5;1371:168-76. doi: 10.1016/j.chroma.2014.10.054. Epub 2014 Oct 24.
10
Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds.纳米结构脂质体系作为一种改善钌(II)化合物体外细胞毒性的策略。
Molecules. 2014 May 9;19(5):5999-6008. doi: 10.3390/molecules19055999.